If you asked me if I would choose Ansarada as a partner in the M&A process again, I would certainly say yes.” Dr. Markus Rinecker, Definiens.
In November 2014, AstraZeneca announced that MedImmune, its global biologics research and development arm, had entered into an agreement to acquire Definiens, a privately held company that pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumor tissue.
During the M&A process Definiens used Ansarada’s data room.
“We chose to use Ansarada’s Data Room solution to simplify the due diligence process and to give global access to the large amount of requested data. It was quick to set up, and we were ready to use it within a day,” says Definiens’ CFO Dr. Markus Rinecker.
“In the beginning of the M&A process we needed some help in preparing our data room and we took advantage of the well-organized support team which was available to us at anytime.
“After closing we could count on the friendly and helpful experts in the support team to get our archive exactly the way we needed it. If you asked me if I would choose Ansarada as a partner in the M&A process again, I would certainly say yes.”